APPILI THERAPEUTICS INC-CL A (APLI.CA) Fundamental Analysis & Valuation
TSX:APLI • CA03783R1073
Current stock price
0.015 CAD
-0.01 (-25%)
Last:
This APLI.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. APLI.CA Profitability Analysis
1.1 Basic Checks
- In the past year APLI has reported negative net income.
- APLI had a negative operating cash flow in the past year.
- In the past 5 years APLI always reported negative net income.
- In the past 5 years APLI reported 4 times negative operating cash flow.
1.2 Ratios
- The Return On Assets of APLI (-479.05%) is worse than 96.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -479.05% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-211.81%
ROA(5y)-203.41%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for APLI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. APLI.CA Health Analysis
2.1 Basic Checks
- APLI does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for APLI remains at a similar level compared to 1 year ago.
- The number of shares outstanding for APLI has been increased compared to 5 years ago.
- Compared to 1 year ago, APLI has an improved debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of -276.06, we must say that APLI is in the distress zone and has some risk of bankruptcy.
- With a Altman-Z score value of -276.06, APLI is not doing good in the industry: 96.97% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -276.06 |
ROIC/WACCN/A
WACC2.82%
2.3 Liquidity
- APLI has a Current Ratio of 0.03. This is a bad value and indicates that APLI is not financially healthy enough and could expect problems in meeting its short term obligations.
- APLI's Current ratio of 0.03 is on the low side compared to the rest of the industry. APLI is outperformed by 96.97% of its industry peers.
- A Quick Ratio of 0.03 indicates that APLI may have some problems paying its short term obligations.
- The Quick ratio of APLI (0.03) is worse than 96.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.03 | ||
| Quick Ratio | 0.03 |
3. APLI.CA Growth Analysis
3.1 Past
- APLI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.77%, which is quite impressive.
- Looking at the last year, APLI shows a very negative growth in Revenue. The Revenue has decreased by -87.87% in the last year.
- The Revenue for APLI have been decreasing by -12.88% on average. This is quite bad
EPS 1Y (TTM)30.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-72.09%
Revenue 1Y (TTM)-87.87%
Revenue growth 3Y-58.35%
Revenue growth 5Y-12.88%
Sales Q2Q%6.09%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y0%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. APLI.CA Valuation Analysis
4.1 Price/Earnings Ratio
- APLI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for APLI. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. APLI.CA Dividend Analysis
5.1 Amount
- No dividends for APLI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
APLI.CA Fundamentals: All Metrics, Ratios and Statistics
TSX:APLI (3/20/2026, 7:00:00 PM)
0.015
-0.01 (-25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-12 2026-02-12
Earnings (Next)06-23 2026-06-23/amc
Inst Owners10.85%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap1.99M
Revenue(TTM)100.40K
Net Income(TTM)-2.62M
Analysts42.22
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 19.78 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.02
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)0
FCFYN/A
OCF(TTM)0
OCFYN/A
SpS0
BVpS-0.12
TBVpS-0.12
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -479.05% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-211.81%
ROA(5y)-203.41%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.18
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 0% | ||
| Cap/Sales | 0% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.03 | ||
| Quick Ratio | 0.03 | ||
| Altman-Z | -276.06 |
F-Score3
WACC2.82%
ROIC/WACCN/A
Cap/Depr(3y)78.19%
Cap/Depr(5y)66.91%
Cap/Sales(3y)1.99%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-72.09%
EPS Next Y0%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-87.87%
Revenue growth 3Y-58.35%
Revenue growth 5Y-12.88%
Sales Q2Q%6.09%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-7.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y99.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y99.63%
OCF growth 3YN/A
OCF growth 5YN/A
APPILI THERAPEUTICS INC-CL A / APLI.CA Fundamental Analysis FAQ
What is the ChartMill fundamental rating of APPILI THERAPEUTICS INC-CL A (APLI.CA) stock?
ChartMill assigns a fundamental rating of 0 / 10 to APLI.CA.
What is the valuation status of APPILI THERAPEUTICS INC-CL A (APLI.CA) stock?
ChartMill assigns a valuation rating of 0 / 10 to APPILI THERAPEUTICS INC-CL A (APLI.CA). This can be considered as Overvalued.
What is the profitability of APLI stock?
APPILI THERAPEUTICS INC-CL A (APLI.CA) has a profitability rating of 0 / 10.